作者
David T. Davies,Simon Leiris,Magdalena Zalacaín,Nicolas Sprynski,Jérôme Castandet,Justine Bousquet,Clarisse Lozano,Agustina Llanos,Laethitia Alibaud,Srinivas Vasa,Ramesh Pattipati,Ravindar Valige,Bhaskar Kummari,Srinivasu Pothukanuri,Cyntia De Piano,Ian Morrissey,Kirsty Holden,Peter Warn,Francesca Marcoccia,Manuela Benvenuti,Cecilia Pozzi,Giusy Tassone,Stefano Mangani,Jean‐Denis Docquier,T. David Pallin,Richard L. Elliot,Marc Lemonnier,Martin Everett
摘要
The diazabicyclooctanes (DBOs) are a class of serine β-lactamase (SBL) inhibitors that use a strained urea moiety as the warhead to react with the active serine residue in the active site of SBLs. The first in-class drug, avibactam, as well as several other recently approved DBOs (e.g., relebactam) or those in clinical development (e.g., nacubactam and zidebactam) potentiate activity of β-lactam antibiotics, to various extents, against carbapenem-resistant Enterobacterales (CRE) carrying class A, C, and D SBLs; however, none of these are able to rescue the activity of β-lactam antibiotics against carbapenem-resistant Acinetobacter baumannii (CRAB), a WHO "critical priority pathogen" producing class D OXA-type SBLs. Herein, we describe the chemical optimization and resulting structure–activity relationship, leading to the discovery of a novel DBO, ANT3310, which uniquely has a fluorine atom replacing the carboxamide and stands apart from the current DBOs in restoring carbapenem activity against OXA-CRAB as well as SBL-carrying CRE pathogens.